New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:26 EDTPCYC, INCYNomura is a buyer of Incyte and Pharmacyclics into ASCO meetings
Nomura is a buyer of Incyte (INCY) and Pharmacyclics (PCYC) following the ASCO abstract releases. The firm expects 50mg dose data on June 2 to meet investor expectations and for shares to recover. For Pharmacyclics, the analyst expects investor focus to be on negativity rates of Phase I/II trial of competitor ABT-199 + Rituxan and Imbruvica RESONATE Phase III data on June 3.
News For INCY;PCYC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 5, 2015
06:23 EDTINCYIncyte management to meet with Leerink
Subscribe for More Information
May 1, 2015
17:04 EDTPCYCAbbVie extends exchange offer to acquire Pharmacyclics
AbbVie (ABBV) announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics (PCYC) to 5:00 pm ET on May 15. The depositary of the exchange offer has advised that, as of 4:00 pm ET, on May 1, a total of approximately 51.47M shares of Pharmacyclics common stock were validly tendered and not properly withdrawn in the exchange offer. All other terms and conditions of the exchange offer remain unchanged.
12:26 EDTPCYCBiogen patent challenged by Kyle Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1-20 of US patent 8,399,514 held by Biogen (BIIB), according to a USPTO filing. The patent is related to the company's multiple sclerosis drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Celgene (CELG), Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). PRICE ACTION: Shares of Biogen are up 3% to $385.29 in afternoon trading.
09:21 EDTPCYCPharmacyclics reports Q1 worldwide Imbruvica revenue $247M
09:20 EDTPCYCPharmacyclics reports Q1 non-GAAP EPS 43c, consensus 11c
Subscribe for More Information
08:10 EDTINCYIncyte price target raised to $115 from $90 at Leerink
Subscribe for More Information
April 30, 2015
12:43 EDTINCYIncyte price target raised to $107 from $84 at Brean Capital
Subscribe for More Information
09:06 EDTINCYIncyte receives orphan status for Hodgkin lymphoma treatment
Subscribe for More Information
07:19 EDTINCYIncyte reports Q1 EPS (11c) consensus (10c)
Reports Q1 revenue $159.3M, consensus $155.21M.
April 23, 2015
10:02 EDTPCYCAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:20 EDTPCYCCelgene patent latest to be challenged by Hayman Capital's Bass
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 110 of U.S. Patent No. 6,045,501 held by Celgene (CELG), according to a USPTO filing. The 501 patent claims methods for delivering a drug, including a teratogenic drug, to a patient while preventing the exposure of a fetus or other contraindicated individuals to the drug. The patent is related to the company's Revlimid drug. BACKGROUND: Previously, the same coalition requested an Inter Partes Review of patents held by Pharmacyclics (PCYC), Acorda Therapeutics (ACOR), Shire (SHPG) and Jazz Pharmaceuticals (JAZZ). On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Celgene are down 0.5% to $114.92 in pre-market trading.
09:07 EDTPCYCAbbVie says remains on track to complete Pharmacyclics acquisition in Q2
April 22, 2015
14:08 EDTPCYCEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use